Rinatabart sesutecan (Rina-S) is an antibody-drug conjugate that targets folate receptor-alpha (FRα) and delivers a TOP1 inhibitor on to most cancers cells, based on a press launch, which went on to notice that within the part 2 RAINFOL-01 medical trial, Rina-S demonstrated antitumor exercise in sufferers with superior ovarian most cancers who had obtained a number of prior remedies.
Up to date findings from RAINFOL-01 confirmed that sufferers handled with Rina-S at a dose of 120 milligrams per sq. meter skilled a confirmed goal response fee of 55.6%. The median period of response had not but been reached on the time of research. These outcomes had been noticed whatever the stage of FRα expression on the tumor cells.
Notably, FRα is a protein generally discovered on the floor of most cancers cells, based on the Nationwide Institutes of Well being, and is produced by the FOLR1 gene, serving as a helpful goal for therapies that purpose to assault most cancers cells.
In an interview with CURE, Dr. Elizabeth Okay. Lee, a medical oncologist and doctor within the gynecologic oncology program at Dana-Farber Most cancers Institute, in Boston, dives into the information and what this implies for sufferers.
Lee additionally serves because the gynecologic oncology program’s liaison to the Middle for Most cancers Therapeutics Innovation at Dana-Farber Most cancers Institute, and can be an teacher in drugs at Harvard Medical College.
Transcript:
We’re all very inspired by the preliminary exercise of Rina-S throughout the dose growth cohort of ovarian most cancers sufferers in RAINFALL-01 — I do know there are various completely different names and trial numbers. This preliminary exercise has led to Half C of RAINFALL-01, which is a roughly 100-patient dose growth particularly in sufferers with platinum-resistant ovarian most cancers.
It is vital to notice that if a affected person has a folate receptor alpha expression stage that meets the standards for receiving Elahere [mirvetuximab soravtansine], they’re required to have obtained it. I feel this additionally touches on a recurring query within the antibody-drug conjugate house concerning the sequencing of various antibody-drug conjugates.
[Looking] again to 2024 [conference data], we famous a handful of sufferers who had obtained Elahere and had had goal lesion reductions and responses with Rina-S. Actually, having many extra sufferers, hopefully round 100 sufferers in Half C of RAINFALL-01, with hopefully many extra having obtained Elahere, will assist bolster that knowledge. Then, we’ll get a greater thought of the exercise of Rina-S even within the post-Elahere setting.
Half C of RAINFALL-01 is presently enrolling and is energetic at a number of websites, though it isn’t but totally enrolled. The information from Half B1 has additionally knowledgeable the randomized part three trial that you simply simply talked about. This randomized part three trial will examine Rina-S at a dose of 120 milligrams per meter squared in comparison with investigator’s alternative chemotherapy. It is going to be a 1:1 randomization, with sufferers assigned to at least one remedy arm or the opposite. This will probably be a reasonably large examine, and hopefully, we are going to get the clearest sense of the exercise of Rina-S from it.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
